Embedded Files
News: Preclinical study shows complete remission of pancreatic cancer from a SINGLE treatment
Our patented magnetoelectric nano-therapy technology has been proven in multiple animal experiments to achieve multi‑fold survival gains in aggressive cancer models without damaging reactions and side effects typical of chemo- and immuno-therapies. Most recently, a research team at NCI Moffitt Cancer Center achieved complete PDAC tumor ablation in one‑third of treated mice and a threefold median reduction in tumor volume using a single treatment (published in Advanced Science in Nov 2025)
Our patented magnetoelectric nano-therapy technology has been proven in multiple animal experiments to achieve multi‑fold survival gains in aggressive cancer models without damaging reactions and side effects typical of chemo- and immuno-therapies. Most recently, a research team at NCI Moffitt Cancer Center achieved complete PDAC tumor ablation in one‑third of treated mice and a threefold median reduction in tumor volume using a single treatment (published in Advanced Science in Nov 2025)
- Cancer treatment using IV-injected biocompatible magnetoelectric nanoparticles to target and generate strong electric field directly on cancer cells to cause cell death when activated by a magnetic field (e.g., from MRI imaging), no chemotherapy or immunotherapy drugs and their associated hard-to-bear side effects
We showed that Magnetoelectric Nanoparticles (MENPs), when activated by a magnetic field, provide a minimally invasive, drug-free, effective theranostic (diagnose and treat at the same time) treatment to the most deadly form of pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) which has the lowest survival rate among all cancers.
Experiments at NCI Moffitt Cancer Center on PDAC xenograft mice showed that a single MENP treatment achieved a threefold median reduction in tumor volume and complete tumor responses in 33.3% of mice at 300 and 600 µg doses (N = 17) and significantly longer mean overall survival as compared to the control cohorts (54.1 vs 28.8 days, χ2 = 40.14, p = 0.045), without evident toxicity in any imaged organ. In contrast, mice receiving subtherapeutic doses, non-activated MENPs, or saline controls showed no significant response.
Currently there is no effective treatment to PDAC and PDAC patients' five-year survival rate is only 8%, lowest among all cancers.
Time-to-event waterfall plot. After a single treatment, four mice achieved a Complete Response (as determined via exam and MRI). After achieving a CR, none of the mice experienced any evidence of disease recurrence. All other mice had eventual tumor growth that met predetermined euthanasia endpoints. Repeated treatments will further increase the CR rate.
This treatment is applicable to many other types of hard-to-treat cancers, and survival rate and complete response rate should increase from repeated treatments.
Read the full paper in Advanced Science: Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models
Read our paper in Advanced Theory and Simulations on the mechanism of the treatment Physics of Selective Targeting of Cancer Cells by Magnetoelectric Nanoparticles: Exploring the Role of Conductivity and Capacitance in Tumor-Specific Attraction
Dr. Sakhrat Khizroev, later joined by Dr. Ping Liang, pioneered and advanced the technology of MENPs and its medical applications, including cancer treatment, intracellular drug delivery, neuromodulation, brain-computer interface, since 2011 with contribution over the years from their teams at University of Miami and Cellular Nanomed Inc, and collaborators at Indiana University School of Medicine, CMU and most recently NCI Moffitt Cancer Center.
Page updated
Google Sites
Report abuse